Cocrystal Pharma, Inc. announced that it was added to the Russell Microcap® Index at the conclusion of the Russell indexes annual reconstitution on June 22, 2018.
ATLANTA, GA and BOTHELL, WA, June 25, 2018 (GLOBE NEWSWIRE) -- CoCrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses and noroviruses, announced today that it was added to the Russell Microcap® Index at the conclusion of the Russell indexes annual reconstitution on June 22, 2018.
Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell, a leading global index provider, determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Gary Wilcox, Vice Chairman and Chief Executive Officer of Cocrystal, commented, “We are pleased to have been included in this year’s FTSE Russell Microcap® Index. Our inclusion is another step toward further expanding our investor audience and establishing a strong foundation to build shareholder value in the near and long term.”
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. The Russell Microcap® Index is one of the most widely used small cap indexes by institutional investors. Approximately 1,500 securities are included in the Russell Microcap® Index, with market capitalizations ranging from $30 million to $1.1 billion. For more information on the Russell Microcap® Index and the index reconstitution, go to the Russell Reconstitution section on the FTSE Russell website.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HepC. Phase 1b studies in HepC infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 48% of the Company. Corporate investors include OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Investor and Media Contact: Jenene Thomas Communications, LLC (833) 475-8247 COCP@jtcir.com
